SpinalCyte, LLC Receives New Japanese Patent
HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Japanese Patent No. 6151006, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.”
“This new Japanese patent demonstrates the unique international protection we are achieving with respect to our fibroblast technology and builds on our international intellectual property portfolio for using fibroblasts to regrow cartilage.”
The technology described in the patent involves preparing a cell/scaffold composition wherein the cells are chondrocytes or chondrocyte-like cells. The patent calls for applying human dermal fibroblasts (HDFs) to the scaffold and subjecting the fibroblasts to mechanical stress, hypoxia and intermittent hydrostatic pressure. Further, the technology described uses a bone morphogenetic growth factor.
“This new Japanese patent demonstrates the unique international protection we are achieving with respect to our fibroblast technology and builds on our international intellectual property portfolio for using fibroblasts to regrow cartilage.” said Pete O’Heeron, Chief Executive Officer, SpinalCyte.
With this addition, SpinalCyte’s portfolio now includes 23 U.S. and foreign patents issued and directly owned by the company, along with 46 patents pending.
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. Currently, SpinalCyte holds 23 U.S. and international issued patents and has filed for an additional 46 patents pending. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement for biologics and cell therapy.